CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis
3.4 Clinical trials
3.5 Government regulations
3.6 Patent study
3.7 Market share analysis (2015)
3.8 Market dynamics

3.8.1 Drivers

3.8.1.1 Increase in the number of new cancer cases
3.8.1.2 Rising adoption of SPECT and PET Scans
3.8.1.3 Increase in preference for radiotaion therapy for cancer treatment
3.8.1.4 Developments in imaging technologies using radiopharmaceuticals

3.8.2 Restraints

3.8.2.1 Supply volatility, logistical challenges and stringent regulatory Policies
3.8.2.2 Competition from conventional alternative diagnostic procedures

3.8.3 Opportunities

3.8.3.1 Multilateral supply agreements between countries
3.8.3.2 Advances in neurological applications

CHAPTER 4 WORLD RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.2 Diagnostics

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Therapeutics

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.1 Biochemistry research

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast

CHAPTER 5 WORLD RADIOPHARMACEUTICALS MARKET, BY MODALITY, 2014-2022

5.1 Overview

5.1.1 Market size and forecast

5.2 SPECT (Single-Photon Emission Computed Tomography)

5.2.1 Market size and forecast

5.2.1.1 Iodine 123
5.2.1.2 Technetium 99m
5.2.1.3 Xenon 133
5.2.1.4 Thallium 201
5.2.1.5 Fluorine 18
5.2.1.6 Others

5.3 PET (Positron Emission Tomography)

5.3.1 Market size and forecast

5.3.1.1 Rubidium 82
5.3.1.2 Fluorine 18
5.3.1.3 Others

5.4 Beta-emitters

5.4.1 Market size and forecast

5.4.1.1 Phosphorus 32
5.4.1.2 Iodine 131
5.4.1.3 Strontium 89
5.4.1.4 Yttrium 90
5.4.1.5 Samarium 153
5.4.1.6 Rhenium 186/188
5.4.1.7 Others

5.5 Alpha-emitters

5.5.1 Market size and forecast

5.5.1.1 Radium 223
5.5.1.2 Bismuth 213
5.5.1.3 Others

5.6 Brachytherapy

5.6.1 Market size and forecast

5.6.1.1 Palladium 103
5.6.1.2 Iodine 125
5.6.1.3 Cesium 131
5.6.1.4 Others

CHAPTER 6 WORLD RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Oncology

6.2.1 Market size and forecast

6.3 Cardiology

6.3.1 Market size and forecast

6.4 Thyroid

6.4.1 Market size and forecast

6.5 Neurology

6.5.1 Market size and forecast

6.6 Others

6.6.1 Market size and forecast

CHAPTER 7 WORLD RADIOPHARMACEUTICALS MARKET, BY END-USER, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Hospitals and diagnostic centers

7.2.1 Market size and forecast

7.3 Research institutes

7.3.1 Market size and forecast

CHAPTER 8 WORLD RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast

8.2.3.1 U.S. market size and forecast
8.2.3.2 Canada market size and forecast
8.2.3.3 Mexico market size and forecast

8.3 Europe

8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast

8.3.3.1 Belarus market size and forecast
8.3.3.2 Czech Republic market size and forecast
8.3.3.3 Greece market size and forecast
8.3.3.4 Hungary market size and forecast
8.3.3.5 Rest of Europe market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.4.3.1 China market size and forecast
8.4.3.2 India market size and forecast
8.4.3.3 South Korea market size and forecast
8.4.3.4 Pakistan market size and forecast
8.4.3.5 Rest of Asia Pacific market size and forecast

8.5 LAMEA

8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast

8.5.3.1 Brazil market size and forecast
8.5.3.2 Argentina market size and forecast
8.5.3.3 South Africa market size and forecast
8.5.3.4 Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 Mallinckrodt plc.

9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Business performance
9.1.5 Key strategies and developments
9.1.6 SWOT analysis

9.2 General Electric Co.

9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies and developments
9.2.6 SWOT analysis

9.3 Medtronic, plc. (Covidien, acquired by Medtronic)

9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Business performance
9.3.5 SWOT analysis

9.4 Bayer AG

9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Business performance
9.4.5 Key strategies and developments
9.4.6 SWOT analysis

9.5 Cardinal Health, Inc.

9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Business performance
9.5.4 SWOT analysis

9.6 Lantheus Medical Imaging, Inc.

9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments
9.6.5 SWOT analysis

9.7 IBA Group

9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments
9.7.6 SWOT analysis

9.8 Bracco Imaging S.p.A

9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments
9.8.6 SWOT analysis

9.9 NTP Radioisotopes SOC Ltd.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Key strategies and developments
9.9.5 SWOT analysis

9.10 Advanced Accelerator Applications S.A.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Key strategies and developments
9.10.5 SWOT analysis

List of Tables

TABLE 1 CLINICAL TRIALS FOR RADIOPHARMACEUTICALS
TABLE 2 WORLD RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 3 WORLD RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTICS, 2014-2022 ($MILLION)
TABLE 4 WORLD RADIOPHARMACEUTICALS MARKET FOR THERAPEUTICS, 2014-2022 ($MILLION)
TABLE 5 WORLD RADIOPHARMACEUTICALS MARKET FOR BIOCHEMISTRY RESEARCH, 2014-2022 ($MILLION)
TABLE 6 WORLD RADIOPHARMACEUTICALS MARKET, BY MODALITY, 2014-2022 ($MILLION)
TABLE 7 WORLD RADIOPHARMACEUTICALS MARKET FOR SPECT, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 WORLD RADIOPHARMACEUTICALS MARKET FOR PET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 WORLD BETA-EMITTERS RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10 WORLD ALPHA-EMITTERS RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 WORLD BRACHYTHERAPY RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 WORLD RADIOPHARMACEUTICALS MARKET, BY NUMBER OF PROCEDURES, 2014-2022
TABLE 13 WORLD RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 14 WORLD RADIOPHARMACEUTICALS MARKET FOR ONCOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 WORLD RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 WORLD RADIOPHARMACEUTICALS MARKET FOR THYROID, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 WORLD RADIOPHARMACEUTICALS MARKET FOR NEUROLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 WORLD RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 WORLD RADIOPHARMACEUTICALS MARKET, BY END-USERS, 2014-2022 ($MILLION)
TABLE 20 WORLD RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21 WORLD RADIOPHARMACEUTICALS MARKET FOR RESEARCH INSTITUTES, BY GEOGRAPHY, 2014-2022 ($MILLION
TABLE 22 WORLD RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 24 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 25 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 26 EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 27 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 28 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29 LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 30 LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 31 MALLINCKRODT PLC: COMPANY SNAPSHOT
TABLE 32 STRATASYS LTD: OPERATING SEGMENTS
TABLE 33 GENERAL ELECTRIC: COMPANY SNAPSHOT
TABLE 34 STRATASYS LTD.: OPERATING SEGMENTS
TABLE 35 MEDTRONIC INC.: COMPANY SNAPSHOT
TABLE 36 MEDTRONIC INC.: OPERATING SEGEMENTS
TABLE 37 BAYER : COMPANY SNAPSHOT
TABLE 38 BAYER: OPERATING SEGMENTS
TABLE 39 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
TABLE 40 LANTHEUS: COMPANY SNAPSHOT
TABLE 41 IBA GROUP: COMPANY SNAPSHOT
TABLE 42 IBA GROUP: OPERATING SEGMENTS
TABLE 43 BRACCO IMAGING: COMPANY SNAPSHOT
TABLE 44 BRACCO IMAGING: OPERATING SEGMENTS
TABLE 45 NTP RADIOISOTOPES: COMPANY SNAPSHOT
TABLE 46 NTP RADIOISOTOPES: OPERATING SEGMENTS
TABLE 47 ADVANCED ACCELERATOR: COMPANY SNAPSHOT
TABLE 48 NTP RADIOISOTOPES: OPERATING SEGMENTS

List of Figures

FIG. 1 TOP INVESTMENT POCKETS IN WORLD RADIOPHARMACEUTICALS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2013 2016)
FIG. 3 PORTERS FIVE FORCE ANALYSIS
FIG. 4 TOP FACTORS IMPACTING WORLD RADIOPHARMACEUTICALS MARKET, 2014-2022
FIG. 5 PRESENT AND ESTIMATED NUMBER OF CANCER PATIENTS WORLDWIDE
FIG. 6 MOST COMMON CANCERS, MEN (INCIDENCE 2012)
FIG. 7 MOST COMMON CANCERS, WOMEN (INCIDENCE 2012)
FIG. 8 U.S. RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 9 CANADA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 10 MEXICO RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 11 BELARUS RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 12 CZECH REPUBLIC RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 13 GREECE RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 14 HUNGARY RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 15 REST OF EUROPE RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 16 CHINA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 17 INDIA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 18 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 19 PAKISTAN RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 20 REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 21 BRAZIL RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 22 ARGENTINA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 23 SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 24 REST OF LAMEA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
FIG. 25 MALLINCKRODT PLC: REVENUE, 2013-2015 ($MILLION)
FIG. 26 MALLINCKRODT PLC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 27 MALLINCKRODT PLC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 28 MALLINCKRODT PLC.: SWOT ANALYSIS
FIG. 29 GENERAL ELECTRIC: REVENUE, 2013-2015 ($MILLION)
FIG. 30 GENERAL ELECTRIC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 31 GENERAL ELECTRIC: REVENUE, BY GEOGRAPHY, 2015(%)
FIG. 32 GENERAL ELECTRIC: SWOT ANALYSIS
FIG. 33 MEDTRONIC: REVENUE, 2013-2015 ($MILLION)
FIG. 34 MEDTRONIC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 35 MEDTRONIC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 36 MEDTRONIC: SWOT ANALYSIS
FIG. 37 BAYER: REVENUE, 2013-2015 ($MILLION)
FIG. 38 BAYER: REVENUE, BY SEGMENTS, 2015 (%)
FIG. 39 BAYER: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 40 BAYER: SWOT ANALYSIS
FIG. 41 CARDINAL HEALTH INC.: REVENUE, 2013-2015 ($MILLION)
FIG. 42 CARDINAL HEALTH INC.: REVENUE, BY SEGMENTS, 2015 (%)
FIG. 43 CARDINAL HEALTH INC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 44 CARDINAL HEALTH, INC.: SWOT ANALYSIS
FIG. 45 LANTHEUS: REVENUE, 2013-2015 ($MILLION)
FIG. 46 LANTHEUS: SWOT ANALYSIS
FIG. 47 IBA GROUP: REVENUE, 2013-2015 ($MILLION)
FIG. 48 IBA GROUP: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 49 IBA GROUP: SWOT ANALYSIS
FIG. 50 BRACCO IMAGING: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 51 BRACCO IMAGING: REVENUE, BY GEOGRAPHY 2015 (%)
FIG. 52 BRACCO IMAGING: SWOT ANALYSIS
FIG. 53 NTP RADIOISOTOPES: SWOT ANALYSIS
FIG. 54 ADVANCED ACCELERATOR: SWOT ANALYSIS

Radiopharmaceuticals is a medical specialty that uses specific radiotracers, and have emerged as an efficient imaging technology in the field of nuclear medicine. The non-invasive nature of radiopharmaceuticals has quickened the diagnosis of various diseases such as cardiovascular diseases, neurological disorders, and cancers. Nowadays, therapeutic radiopharmaceuticals are preferred to conventional therapeutic modalities, such as chemotherapy, in the field of oncology for treating cancers. Radiopharmaceuticals are mostly used in diagnostic applications due to advancements in the field such as hybrid imaging technologies using PET/CT and SPECT/CT.

Convenient therapeutic radiopharmaceuticals procedures have a higher capability of mapping physiological functions and metabolic activities and providing specific information about organ function and dysfunction as compared to conventional imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasonography (US) among others. Furthermore, increase in incidence of cancer & cardiovascular aliments, growing demand for alpha radio immunotherapy-based targeted cancer treatment, need for nuclear imaging techniques, and advancements in radiotracers have opened new avenues for radiopharmaceutical manufactures.

The SPECT and PET radiopharmaceuticals modality are widely used at hospitals and diagnostics centers adopting novel methods of radiolabeling with advanced targeting specificity and better therapeutic efficacy. Therefore, the use of SPECT and PET scans facilitates early and accurate diagnosis of complex diseases such as cancer. Increased usage of SPECT and PET scans in turn fosters the demand for radiopharmaceuticals across varied applications such as cancer, cardiac diseases, neurological diseases, and renal & respiratory diseases, among others. The steady progress in the field of nuclear medicine is expected to continue in the near future, which would eventually help in improving the medical diagnostic sector.

Positron emission tomography (PET) scans are widely used in the medical sector, as they provide better quality images and higher precision diagnosis. The other reasons attributed to the high demand for PET scans include upsurge in R&D activities, especially in developing economies, and wide scope of radiopharmaceutical applications such as thyroid, oncology, and bone pain palliation. The radiopharmaceutical market is dominated by Asia-Pacific region followed by Europe and North America. However, Asia-Pacific region is growing at fastest pace during the study period due to large pool of targeted diseases with unmet medical demands in China and India. The Asia-Pacific radiopharmaceuticals market would offer lucrative growth opportunities to the market players due to improvement in healthcare infrastructure, high disposable incomes, and increasing government initiatives to promote early diagnosis of diseases.